1.Lung cancer prevention and screening: LDCT (low-dose CT) screening reduces death in high-risk groups for sure, but LDCT lung cancer screening is not recommended for high-risk groups. 2.Treatment of early stage NSCLC: thoracoscopic lobectomy is recommended. 3, For early stage (stage I and II) NSCLC: radical surgery with or without adjuvant chemotherapy is still the standard treatment modality, and the main update points are: the scope of radical lymph node dissection, the prognosis of performing mediastinal lymph node dissection or systematic mediastinal lymph node sampling is comparable, and the former does not increase the incidence of comorbidities. adjuvant chemotherapy should be given to the high-risk group in stage B. The high-risk factors include poor differentiation (including neurological The risk factors include poor differentiation (including neuroendocrine carcinoma), vascular invasion, wedge resection, tumor diameter greater than 4 CM, dirty pleural involvement, and high risk of lymph node involvement. Sub lobectomy and wedge resection should have a parenchymal margin greater than 2CM or greater than the nodal diameter. 4.Treatment of locally advanced non-small cell lung cancer: consolidation chemotherapy is recommended after simultaneous radiotherapy. 5.Treatment for N2 positive patients: preoperative neoadjuvant radiotherapy or chemotherapy is optional. 6.Treatment of advanced non-small cell lung cancer: routine EGFR mutation testing is recommended for non-squamous cancer patients. Routine EGFR mutation and ALK gene testing is not recommended for squamous carcinoma, except in cases of non-smoking or few biopsy specimens. 7. Predictive and prognostic molecular markers incorporated into EML4-ALK:crizotinib as a targeted new drug of choice. In China, the incidence of EML4-ALK fusion gene is about 16%. Crizotinib is a new targeted therapeutic agent for EML4-ALK, which is a TKI for ALK and growth factor receptor protein (MET), and crizotinib has a disease vacancy rate of up to 90% in patients with EML4-ALK mutant advanced NSCLC.